Nov. 16 at 12:01 PM
HC Wainwright & Co. Maintains Buy on
$SMTI, Lowers Price Target 🚀
✅ HC Wainwright & Co. reiterated a "Buy" rating for Sanara MedTech (SMTI), signaling continued confidence in its core business.
✅ The firm adjusted its price target for SMTI downward from
$54.00 to
$36.00.
✅ This price target revision likely reflects the near-term financial impact of discontinuing the Tissue Health Plus (THP) segment, which entails a cash investment in the latter half of 2025.
✅ The strategic decision to exit THP aims to reallocate resources to the higher-potential surgical business, which demonstrated strong revenue growth in Q3.
✅ Analysts anticipate a deceleration in revenue growth for Q4, potentially contributing to the revised price target.
